Clinical Trials Update: July 10, 2006
Atrial Fibrillation Prostate Cancer Diabetes - Type 2
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This research study is looking at the safety and effectiveness of an investigational drug for individuals with atrial fibrillation.
Successful volunteers should be at leat 18 years old with a documented history of atrial fibrillation. Qualified participants will receive study-related medical care and medication at no cost.
The research site is in Worcester, Mass.
This is a three-year placebo-controlled study with dutasteride to assess the efficacy and safety in extending time to progression of prostate cancer in men diagnosed with low-risk, localized disease who are undergoing expectant management.
Those who may qualify are males between the ages of 50 and 80 who have biopsy-proven, low-risk localized prostate cancer and are active in expectant management within one year (biopsy must have been obtained within 6 months of screening) and have no history of another cancer within 5 years that could affect the diagnosis of prostate cancer.
The research site is in Albuquerque, N.M.
Diabetes - Type 2
Novartis Pharmaceutical Corp. is conducting research to determine the safety and effectiveness of adding the investigational drug vildagliptin to the metformin treatment of patients with diabetes.
This 24-week research study is for candidates between the ages of 18 and 78 who cannot control their type 2 diabetes with metformin (Glucophage ® ) tablets, diet and exercise.
Successful candidates for this study must not have a history of type 1 diabetes or any heart conditions such as heart attack, stroke, bypass surgery or heart failure. Research sites are located across the United States.
Copyright 2006 Thomson CenterWatch. All rights reserved.